Egalet Corporation announced positive top-line results from a phase 3 study evaluating the efficacy and safety of Egalet-002, an abuse-deterrent, extended-release oxycodone developed using a unique application of the Guardian™ Technology. This second of two Phase 3 studies was a multicenter, double-blind, enriched enrollment, randomized withdrawal, efficacy and safety study of Egalet-002 versus placebo in opioid-experienced and opioid-naïve patients with moderate-to-severe chronic low back pain. The study met its primary endpoint, which showed a statistically significant difference in average pain intensity from baseline (at randomization) to week 16 between the Egalet-002 and placebo treatment groups (p<0.0001). In a previously announced Phase 3 safety study, Egalet-002 was generally well-tolerated and no new safety concerns were identified in this study.